Analysis of the TCGA database revealed that CDK13 is heterozygously deleteriously mutated in 4.6% of melanoma samples, with a notable enrichment in the ATP-binding site of the kinase domain.227 Patient-derived CDK13 mutations act as dominant-negative on wild-type CDK13, thereby accelerating oncogenesis in both in vitro and in vivo models of melanoma. The gene discussed is CDK13; the disease is melanoma.